↓ Skip to main content

Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers

Overview of attention for article published in Journal for Immunotherapy of Cancer, July 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
68 X users
facebook
1 Facebook page
googleplus
1 Google+ user

Citations

dimensions_citation
123 Dimensions

Readers on

mendeley
149 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Published in
Journal for Immunotherapy of Cancer, July 2018
DOI 10.1186/s40425-018-0376-0
Pubmed ID
Authors

Muhammad Umair Mushtaq, Athanasios Papadas, Adam Pagenkopf, Evan Flietner, Zachary Morrow, Sibgha Gull Chaudhary, Fotis Asimakopoulos

Abstract

Recent advances in our understanding of the dynamics of cellular cross-talk have highlighted the significance of host-versus-tumor effect that can be harnessed with immune therapies. Tumors exploit immune checkpoints to evade adaptive immune responses. Cancer immunotherapy has witnessed a revolution in the past decade with the development of immune checkpoint inhibitors (ICIs), monoclonal antibodies against cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or their ligands, such as PD1 ligand 1 (PD-L1). ICIs have been reported to have activity against a broad range of tumor types, in both solid organ and hematologic malignancy contexts. However, less than one-third of the patients achieve a durable and meaningful treatment response. Expression of immune checkpoint ligands (e.g., PD-L1), mutational burden and tumor-infiltrating lymphocytes are currently used as biomarkers for predicting response to ICIs. However, they do not reliably predict which patients will benefit from these therapies. There is dire need to discover novel biomarkers to predict treatment efficacy and to identify areas for development of combination strategies to improve response rates. Emerging evidence suggests key roles of tumor extracellular matrix (ECM) components and their proteolytic remodeling products in regulating each step of the cancer-immunity cycle. Here we review tumor matrix dynamics and matrix remodeling in context of anti-tumor immune responses and immunotherapy and propose the exploration of matrix-based biomarkers to identify candidates for immune therapy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 68 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 149 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 149 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 31 21%
Student > Ph. D. Student 18 12%
Student > Master 12 8%
Student > Bachelor 10 7%
Student > Doctoral Student 9 6%
Other 25 17%
Unknown 44 30%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 39 26%
Medicine and Dentistry 17 11%
Agricultural and Biological Sciences 13 9%
Immunology and Microbiology 10 7%
Pharmacology, Toxicology and Pharmaceutical Science 6 4%
Other 15 10%
Unknown 49 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 August 2021.
All research outputs
#1,080,604
of 25,411,814 outputs
Outputs from Journal for Immunotherapy of Cancer
#249
of 3,432 outputs
Outputs of similar age
#23,040
of 341,351 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#9
of 40 outputs
Altmetric has tracked 25,411,814 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,432 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,351 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.